Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Ji Woong Son MD, PhD"'
Autor:
Eunbin Kwag PhD, Soo-Dam Kim MD, PhD, Seong-Hoon Shin MD, PhD, Chulho Oak MD, PhD, So-Jung Park KMD, PhD, Jun-Yong Choi KMD, PhD, Seong Hoon Yoon MD, PhD, In-Cheol Kang PhD, Mi-Kyung Jeong KMD, PhD, Hyun Woo Lee MD, PhD, Sun-Hwi Bang KMD, PhD, Ji Woong Son MD, PhD, Sanghun Lee PhD, Seung Joon Kim MD, PhD, Hwa-Seung Yoo KMD, PhD
Publikováno v:
Integrative Cancer Therapies, Vol 23 (2024)
Background: Lung cancer, especially non-small cell lung cancer (NSCLC), poses a significant health challenge globally due to its high mortality. Afatinib, a second-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), has
Externí odkaz:
https://doaj.org/article/16dc59132dba49268b5fe5b711723fa5
Autor:
Won Kil Lee PhD, Jisoo Myong KMD, PhD, Eunbin Kwag MS, Younmin Shin MS, Ji Woong Son MD, PhD, Byong Chul Yoo PhD, Byoung-Soo Kim KMD, PhD, Hwa-Seung Yoo KMD, PhD, Jeong June Choi PhD
Publikováno v:
Integrative Cancer Therapies, Vol 22 (2023)
Erlotinib is a necessary anticancer treatment for non-small cell lung cancer (NSCLC) patients yet it causes severe side effects such as skin rash. In this study, researchers compared the untargeted compound profiles before and after erlotinib adminis
Externí odkaz:
https://doaj.org/article/8f3cc2b6fadb44439a72437d6bdb0a45
Autor:
Eun-Ju Ko KMD, MS, Eun-Bin Kwag MS, Ji Hye Park KMD, PhD, So-Jung Park KMD, PhD, Ji-Woong Son MD, PhD, Seong-Hun Yoon MD, PhD, Seong-Hun Shin MD, PhD, Hwa-Seung Yoo KMD, PhD
Publikováno v:
Integrative Cancer Therapies, Vol 20 (2021)
Afatinib is a target anticancer drug of the second-generation EGFR TKI type, showing an advantage in treatment effect compared to conventional chemotherapy. However, patients on EGFR-TKI drugs also usually progress after 9 to 13 months according to s
Externí odkaz:
https://doaj.org/article/5bea7c7b971948c1b9e82f8fd0f59c18